Tipsheet
What matters at India’s listed companies
Brief /Earnings / Healthcare

Max Healthcare posts 10% revenue growth, maps ₹1,400 cr Lucknow greenfield hospital

Q4 operating EBITDA up 8% to ₹682 cr; PAT up 3%. Brownfield capacity expansion underway; Kalinga acquisition completed.

2 earlier stories on Max Healthcare Institute Ltd.
Mkt cap₹99,587 cr
P/E138.97×
ROE11.47%
Debt / eq.0.27
Div yld0.20%
₹1,400 Cr Board-approved greenfield hospital in Lucknow

What's new with Max Healthcare Institute Ltd.

  • Board approved ₹1,400 cr greenfield hospital in Lucknow.
  • Completed acquisition of Kalinga Hospital.
  • Phased commissioning of ~20% brownfield capacity underway.

Why this matters for Max Healthcare Institute Ltd.

Max Healthcare is reinvesting its steady earnings into aggressive capacity expansion. The ₹1,400 cr Lucknow greenfield project and brownfield additions signal confidence in demand, but execution will be key. Margins held steady as top-line grew 10%, giving the company room to fund growth.

What we're watching

  • Timeline for Lucknow hospital construction and commissioning.
  • Occupancy ramp at new brownfield units and Kalinga.
  • Impact of new competition in Max's key markets.

The full read

Max Healthcare's Q4 earnings were in line with the board-meeting flash: revenue up 10% to ₹2,664 cr, EBITDA up 8% to ₹682 cr, PAT up 3% to ₹387 cr. The fresh news is what Max plans to do with the cash. The board approved a ₹1,400 cr greenfield hospital in Lucknow — the company's first foray into Uttar Pradesh's capital. Separately, the acquisition of Kalinga Hospital has closed, adding beds, and around a fifth of its previously announced brownfield capacity is being commissioned in phases. Max is sustaining its growth while making large forward bets. The market already had the headline numbers; now it has the expansion roadmap.

Mentioned: ₹1,400 cr greenfield hospital in Lucknow · Kalinga Hospital acquisition
Primary source BSE · NSE · Tijori

Our reading of the company's own disclosure. Always confirm against the original source.